Literature DB >> 30238542

Hospitalisations and emergency department visits in cancer patients receiving systemic therapy: Systematic review and meta-analysis.

Rebecca M Prince1,2, Melanie Powis1, Alona Zer3,4, Eshetu G Atenafu1,2, Monika K Krzyzanowska1,2.   

Abstract

Emergency department visits and hospitalisations (ED+H) during systemic therapy are undesirable for both patients and the health system. We undertook a systematic literature review and meta-analysis to evaluate the frequency of unplanned all-cause and treatment-related ED+H among adults receiving adjuvant or palliative-intent systemic therapy for all cancers. Randomised controlled trials (RCT) and observational studies (OS) reporting ED+H were identified from Medline and EMBASE from inception to June 2016. Quality was assessed using modified STROBE, CONSORT or PRISMA guidelines, depending on study type. A total of 112 OS (308,662 patients) and 26 RCTs (16,081 patients) met inclusion criteria. Most articles focused on palliative treatment (59%) delivered as first-line, in breast, lung and colorectal cancers. Only 20 articles reported ED frequency. Treatment-related and all-cause hospitalisations were more common in routine practice than in RCTs (29% vs. 16% and 42% vs. 28% respectively); frequency varied by treatment intent and tumour site. Methodological issues were common, particularly poor definition of the at-risk period. Hospitalisations are common, especially in unselected populations, but few articles report this and do so poorly. Routine, standardised reporting of ED+H during chemotherapy should be included in RCT reports and evaluated in routine care following adoption of new treatments.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  chemotherapy; chemotherapy toxicities; emergency department visits; hospitalisations

Mesh:

Substances:

Year:  2018        PMID: 30238542     DOI: 10.1111/ecc.12909

Source DB:  PubMed          Journal:  Eur J Cancer Care (Engl)        ISSN: 0961-5423            Impact factor:   2.520


  12 in total

1.  Cross-Canada differences in early-stage breast cancer treatment and acute-care use.

Authors:  M Powis; P Groome; N Biswanger; C Kendell; K M Decker; E Grunfeld; M L McBride; R Urquhart; M Winget; G A Porter; M K Krzyzanowska
Journal:  Curr Oncol       Date:  2019-10-01       Impact factor: 3.677

2.  Main reasons and predictive factors of cancer-related emergency department visits in a Hungarian tertiary care center.

Authors:  Márton Koch; Csaba Varga; Viktor Soós; Lilla Prenek; Lili Porcsa; Alíz Szakáll; Gergely Bilics; Balázs Hunka; Szabolcs Bellyei; János Girán; István Kiss; Éva Pozsgai
Journal:  BMC Emerg Med       Date:  2022-06-23

3.  Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting.

Authors:  Laura A Petrillo; Kerry L Reynolds; Sienna M Durbin; Leyre Zubiri; Andrzej Niemierko; Aditya Bardia; Ryan J Sullivan; Corey McEwen; Therese M Mulvey; Ian M Allen; Donald P Lawrence; Justine V Cohen; Ephraim P Hochberg; David P Ryan
Journal:  Oncologist       Date:  2020-11-08

4.  Risk Factors for Emergency Room and Hospital Care Among Patients With Solid Tumors on Immune Checkpoint Inhibitor Therapy.

Authors:  Anish B Parikh; Xiaobo Zhong; George Mellgard; Qian Qin; Vaibhav G Patel; Bo Wang; Parissa Alerasool; Philip Garcia; Amanda Leiter; Emily J Gallagher; Steven Clinton; Amir Mortazavi; Paul Monk; Edmund Folefac; Ming Yin; Yuanquan Yang; Matthew Galsky; William K Oh; Che-Kai Tsao
Journal:  Am J Clin Oncol       Date:  2021-03-01       Impact factor: 2.787

5.  Perspective of Oncology Patients During COVID-19 Pandemic: A Prospective Observational Study From India.

Authors:  Joydeep Ghosh; Sandip Ganguly; Debapriya Mondal; Prashant Pandey; Deepak Dabkara; Bivas Biswas
Journal:  JCO Glob Oncol       Date:  2020-06

6.  Ambulatory Toxicity Management (AToM) Pilot: results of a pilot study of a pro-active, telephone-based intervention to improve toxicity management during chemotherapy for breast cancer.

Authors:  Monika K Krzyzanowska; Cassandra MacKay; Heekyung Han; Maria Eberg; Sonal Gandhi; Nicole B Laferriere; Melanie Powis; Doris Howell; Clare L Atzema; Kelvin K W Chan; Vishal Kukreti; Sandra Mitchell; Marla Nayer; Mark Pasetka; Dafna Knittel-Keren; Erin Redwood
Journal:  Pilot Feasibility Stud       Date:  2019-03-08

7.  Ambulatory Toxicity Management (AToM) in patients receiving adjuvant or neo-adjuvant chemotherapy for early stage breast cancer - a pragmatic cluster randomized trial protocol.

Authors:  Monika K Krzyzanowska; Jim A Julian; Melanie Powis; Doris Howell; Craig C Earle; Katherine A Enright; Nicole Mittmann; Maureen E Trudeau; Eva Grunfeld
Journal:  BMC Cancer       Date:  2019-09-05       Impact factor: 4.430

8.  Development and Validation of a Score to Predict Acute Care Use After Initiation of Systemic Therapy for Cancer.

Authors:  Robert C Grant; Rahim Moineddin; Zhan Yao; Melanie Powis; Vishal Kukreti; Monika K Krzyzanowska
Journal:  JAMA Netw Open       Date:  2019-10-02

9.  Methodological approaches to measuring the incidence of unplanned emergency department presentations by cancer patients receiving systemic anti-cancer therapy: a systematic review.

Authors:  P H Dufton; M F Gerdtz; R Jarden; M Krishnasamy
Journal:  BMC Med Res Methodol       Date:  2022-03-21       Impact factor: 4.615

10.  Socio-demographic and disease related characteristics associated with unplanned emergency department visits by cancer patients: a retrospective cohort study.

Authors:  Polly H Dufton; Allison Drosdowsky; Marie F Gerdtz; Mei Krishnasamy
Journal:  BMC Health Serv Res       Date:  2019-09-06       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.